In this podcast episode, nursing specialist Alina Ladariu discusses her experiences with HyQvia® during the onboarding process of new patients. In conversation with moderator Dr. Marcus Kühn, she points out the requirements for patients to be able to perform the entire procedure independently and elaborates on the benefits and challenges associated with facilitated subcutaneous immunoglobulin (fSCIG) therapy.
Moderator: Dr. med. Marcus Kühn, Specialist in Allergology and Clinical Immunology at Löwenpraxis, Lucerne (website).
Guest: Alina Ladariu, Nursing Specialist at Careformance (website).
Brightcove Video
Resources and Links:
[1] Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé OA, Bernatowska E. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017 Nov 1;6(5):76-83. PMID: 29181272; PMCID: PMC5698561.
[2] Devonshire AL, Makhija M. Approach to primary immunodeficiency. Allergy Asthma Proc. 2019 Nov 1;40(6):465-469. Doi: 10.2500/aap.2019.40.4273. PMID: 31690396.
[3] Epland K, Suez D, Paris K. A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol. 2022 Sep 30;18(1):87. doi: 10.1186/s13223-022-00726-7. PMID: 36180928; PMCID: PMC9526304.
IVIG = Intravenous Immunoglobuline
HyQvia® prescribing information: https://www.swissmedicinfo.ch
Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.
C-APROM/CH/HYQ/0016_08/2024